Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Journal of Veterinary Science ; : 387-393, 2013.
Article in English | WPRIM | ID: wpr-197115

ABSTRACT

Prebiotics modulate microbial composition and ensure a healthy gastrointestinal tract environment that can prevent colon cancer development. These natural dietary compounds are therefore potential chemopreventive agents. Thirty Sprague-Dawley rats (4 months old) were experimentally treated with procarcinogen dimethylhydrazine to induce colon cancer development. The rats were randomly assigned to three groups: a control group (CG), a group treated with dimethylhydrazine (DMH), and a group given DMH and inulin, a prebiotic (DMH+PRE). The effects of inulin on the activities of bacterial glycolytic enzymes, short-chain fatty acids, coliform and lactobacilli counts, cytokine levels, and cyclooxygenase-2 (COX-2) and transcription nuclear factor kappa beta (NFkappaB) immunoreactivity were measured. Inulin significantly decreased coliform counts (p < 0.01), increased lactobacilli counts (p < 0.001), and decreased the activity of beta-glucuronidase (p < 0.01). Butyric and propionic concentrations were decreased in the DMH group. Inulin increased its concentration that had been reduced by DMH. Inulin decreased the numbers of COX-2- and NFkappaB-positive cells in the tunica mucosae and tela submucosae of the colon. The expression of IL-2, TNFalpha, and IL-10 was also diminished. This 28-week study showed that dietary intake of inulin prevents preneoplastic changes and inflammation that promote colon cancer development.


Subject(s)
Animals , Female , Male , Rats , Bacterial Proteins/genetics , Colon/enzymology , Colonic Neoplasms/chemically induced , Colony Count, Microbial , Cyclooxygenase 2/genetics , Cytokines/blood , Diet , Dietary Supplements/analysis , Dimethylhydrazines/toxicity , Enterobacteriaceae/drug effects , Fatty Acids, Volatile/genetics , Gene Expression Regulation/drug effects , Inulin/administration & dosage , Lactobacillaceae/drug effects , NF-kappa B/genetics , Prebiotics/analysis , Rats, Sprague-Dawley
2.
Experimental & Molecular Medicine ; : 717-727, 2009.
Article in English | WPRIM | ID: wpr-71511

ABSTRACT

Triptolide, a diterpenoid triepoxide from the traditional Chinese medicinal herb Tripterygium wilfordii Hook. f., is a potential treatment for autoimmune diseases as well a possible anti-tumor agent. It inhibits proliferation of coloretal cancer cells in vitro and in vivo. In this study, its ability to block progress of colitis to colon cancer, and its molecular mechanism of action are investigated. A mouse model for colitis-induced colorectal cancer was used to test the effect of triptolide on cancer progression. Treatment of mice with triptolide decreased the incidence of colon cancer formation, and increased survival rate. Moreover, triptolide decreased the incidence of tumors in nude mice inoculated with cultured colon cancer cells dose-dependently. In vitro, triptolide inhibited the proliferation, migration and colony formation of colon cancer cells. Secretion of IL6 and levels of JAK1, IL6R and phosphorylated STAT3 were all reduced by triptolide treatment. Triptolide prohibited Rac1 activity and blocked cyclin D1 and CDK4 expression, leading to G1 arrest. Triptolide interrupted the IL6R-JAK/STAT pathway that is crucial for cell proliferation, survival, and inflammation. This suggests that triptolide might be a candidate for prevention of colitis induced colon cancer because it reduces inflammation and prevents tumor formation and development.


Subject(s)
Animals , Humans , Male , Mice , Cell Transformation, Neoplastic/drug effects , Colitis/complications , Colonic Neoplasms/chemically induced , Dextran Sulfate/toxicity , Dimethylhydrazines/toxicity , Diterpenes/administration & dosage , Epoxy Compounds/administration & dosage , Interleukin-6/biosynthesis , Janus Kinases/metabolism , Mice, Inbred BALB C , Mice, Inbred ICR , Mice, Nude , Neoplasm Transplantation , Phenanthrenes/administration & dosage , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Tumor Burden/drug effects , rac1 GTP-Binding Protein/biosynthesis
3.
Braz. j. med. biol. res ; 41(4): 311-317, Apr. 2008. graf
Article in English | LILACS | ID: lil-479674

ABSTRACT

Denervation of the colon is protective against the colon cancer; however, the mechanisms involved are unknown. We tested the hypothesis that the denervated colonic mucosa could be less responsive to the action of the chemical carcinogen dimethylhydrazine (DMH). Three groups of 32 male Wistar rats were treated as follows: group 1 (G1) had the colon denervated with 0.3 mL 1.5 mM benzyldimethyltetradecylammonium (benzalkonium chloride, BAC); G2 received a single ip injection of 125 mg/kg DMH; G3 was treated with BAC + the same dose and route of DMH. A control group (Sham, N = 32) did not receive any treatment. Each group was subdivided into four groups according to the sacrifice time (1, 2, 6, and 12 weeks after DMH). Crypt fission index, ß-catenin accumulated crypts, aberrant crypt foci, and cell proliferation were evaluated and analyzed by ANOVA and the Student t-test. G3 animals presented a small number of aberrant crypt foci and low crypt fission index compared to G2 animals after 2 and 12 weeks, respectively. From the second week on, the index of ß-catenin crypt in G3 animals increased slower than in G2 animals. From the 12th week on, G2 animals presented a significant increase in cell proliferation when compared to the other groups. Colonic denervation plays an anticarcinogenic role from early stages of colon cancer development. This finding can be of importance for the study of the role of the enteric nervous system in the carcinogenic process.


Subject(s)
Animals , Male , Rats , Carcinogens/toxicity , Colon/innervation , Colonic Neoplasms/chemically induced , Denervation , Dimethylhydrazines/toxicity , Benzalkonium Compounds , Cell Proliferation , Colon/pathology , Colonic Neoplasms/pathology , Precancerous Conditions/metabolism , Rats, Wistar , Time Factors , Biomarkers, Tumor/metabolism , beta Catenin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL